Ipratropio Bromuro Cipla (Ipratropium Bromide Monohydrate)

Ipratropium bromide works by competitively blocking muscarinic (M3) receptors on airway smooth muscle. This inhibition prevents acetylcholine‑induced calcium influx, leading to relaxation of bronchial smooth muscle and bronchodilation, thereby easing airflow obstruction.

The prescribed dose of Ipratropio Bromuro Cipla is determined by the treating physician based on the patient’s condition, severity, and response to therapy. Typical regimens involve inhalation several times daily, but exact dosing must follow the prescriber’s instructions.

Safety data for ipratropium bromide in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies any possible risk, and a healthcare professional should be consulted.

To order Ipratropio Bromuro Cipla, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and required import documentation.

Ipratropio Bromuro Cipla (ipratropium) is a short‑acting anticholinergic, whereas beta‑agonists such as albuterol provide rapid bronchodilation via a different receptor pathway. Long‑acting anticholinergics like tiotropium have a longer duration of action. Ipratropium is often used as add‑on therapy to achieve complementary bronchodilation.

Store the inhalation solution at room temperature, preferably below 25 °C, in the original container. Protect it from moisture, direct sunlight, and extreme temperatures. Keep the product out of reach of children and do not use after the expiration date.

The product is administered by inhalation, typically using a nebulizer or a metered‑dose inhaler as directed by a healthcare professional. The patient inhales the prescribed dose through the mouthpiece, ensuring proper technique to maximize drug delivery to the lungs.

Serious risks include paradoxical bronchospasm, urinary retention, exacerbation of narrow‑angle glaucoma, and severe allergic reactions such as anaphylaxis. Patients should be instructed to seek immediate medical attention if they experience sudden worsening of breathing, eye pain, difficulty urinating, or signs of an allergic reaction.

Ipratropio Bromuro Cipla should not be used by individuals with known hypersensitivity to ipratropium bromide or any excipients, patients with narrow‑angle glaucoma, significant urinary retention, or those experiencing a severe COPD exacerbation that requires systemic therapy. Contraindications must be confirmed by a healthcare professional.